Antibodies to β2-Glycoprotein-I: Urea Resistance, Binding Specificity, and Association with Thrombosis

    loading  Checking for direct PDF access through Ovid


The aim of the present study was to evaluate the urea resistance and binding characteristics of anti-β2-glycoprotein I (anti-β2GPI) antibodies using standard anticardiolipin (aCL) and anti-β2GPI enzyme immunosorbent assays (ELISAs). Sera from patients with antiphospholipid syndrome (APS) (n = 22) and non-APS (n = 24), positive in a standard aCL ELISA, were tested in an anti-β2GPI ELISA performed in polystyrene-irradiated ELISA plates. Urea resistance aCL and anti-β2GPI ELISAs were performed by measuring the ability of antibodies to recognize antigen in the presence of 2 M urea. The serum dilution after urea treatment (D) expressed as a percentage of the serum dilution without urea treatment (Do) corresponding to the same optical density was defined as residual activity (RA = 100 D/Do). The higher the RA, the higher the resistance of the antibodies to urea. APS compared to non-APS sera had higher aCL binding (absorbance values ranging between 0.180 and 1.400; median, 0.717 vs 0.120-1.273; median, 0.250, respectively; P < 0.004). Six APS patients' sera had low aCL levels but they expressed RA ≥30%. Anti-β2GPI antibodies were detected in 15 of 22 APS vs 3 of 24 non-APS patients (P < 0.03); RA ≥30% was detected in 15 of 22 APS vs 1 of 23 non-APS patients (P < 0.004). Using a CL affinity column, antibodies were purified from three APS anti-β2GPI negative and three non-APS anti-β2GPI-positive patients and tested in a aCL ELISA, using highly purified bovine serum albumin (BSA) as a blocking agent (modified ELISA); reactivity was not detected in two APS and one non-APS sera. On the contrary, the reactivity of the purified antibodies was high when β2GPI was incubated with CL in the ELISA plates; thus some anti-β2GPI negative sera from APS patients recognized the CL/β2GPI complex, rather than CL or β2GPI alone. In conclusion, anti-β2GPI antibodies are common in the APS patients, but a number of such patients recognize the CL/β2GPI complex and not CL or β2GPI. Antibodies to either β2GPI or the CL/β2GPI complex derived from APS sera present a high resistance to urea. Anti-β2GPI antibodies of low urea resistance exist in a minority of non-APS patients with autoimmune disease.

Related Topics

    loading  Loading Related Articles